177 related articles for article (PubMed ID: 36765890)
1. Niclosamide Revitalizes Sorafenib through Insulin-like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma.
Peng SW; Ngo MT; Kuo YC; Teng MH; Guo CL; Lai HC; Chang TS; Huang YH
Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765890
[TBL] [Abstract][Full Text] [Related]
2. A Yes-Associated Protein (YAP) and Insulin-Like Growth Factor 1 Receptor (IGF-1R) Signaling Loop Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma.
Ngo MT; Peng SW; Kuo YC; Lin CY; Wu MH; Chuang CH; Kao CX; Jeng HY; Lin GW; Ling TY; Chang TS; Huang YH
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359714
[TBL] [Abstract][Full Text] [Related]
3. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
4. IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways.
Cai W; Ma Y; Song L; Cao N; Gao J; Zhou S; Tang X
BMC Cancer; 2023 Jan; 23(1):87. PubMed ID: 36698167
[TBL] [Abstract][Full Text] [Related]
5. Inflammation Promotes Expression of Stemness-Related Properties in HBV-Related Hepatocellular Carcinoma.
Chang TS; Chen CL; Wu YC; Liu JJ; Kuo YC; Lee KF; Lin SY; Lin SE; Tung SY; Kuo LM; Tsai YH; Huang YH
PLoS One; 2016; 11(2):e0149897. PubMed ID: 26919045
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
Zhao H; Desai V; Wang J; Epstein DM; Miglarese M; Buck E
Mol Cancer Ther; 2012 Feb; 11(2):503-13. PubMed ID: 22161861
[TBL] [Abstract][Full Text] [Related]
8. Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram.
Zhang G; Wang Y; Fuchs BC; Guo W; Drum DL; Erstad DJ; Shi B; DeLeo AB; Zheng H; Cai L; Zhang L; Tanabe KK; Wang X
Front Oncol; 2022; 12():913736. PubMed ID: 35912209
[TBL] [Abstract][Full Text] [Related]
9. SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3β/CTNNB1 Pathway.
Tang X; Liu B; Zhang C; Tang W; Liang S; Xiao Y; Deng R; Li Z
Front Oncol; 2021; 11():773045. PubMed ID: 34950583
[TBL] [Abstract][Full Text] [Related]
10. LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription.
Lin Z; Xia S; Liang Y; Ji L; Pan Y; Jiang S; Wan Z; Tao L; Chen J; Lin C; Liang X; Xu J; Cai X
Theranostics; 2020; 10(19):8834-8850. PubMed ID: 32754282
[TBL] [Abstract][Full Text] [Related]
11. Ovatodiolide and antrocin synergistically inhibit the stemness and metastatic potential of hepatocellular carcinoma via impairing ribosome biogenesis and modulating ERK/Akt-mTOR signaling axis.
Chen MY; Hsu CH; Setiawan SA; Tzeng DTW; Ma HP; Ong JR; Chu YC; Hsieh MS; Wu ATH; Tzeng YM; Yeh CT
Phytomedicine; 2023 Jan; 108():154478. PubMed ID: 36265255
[TBL] [Abstract][Full Text] [Related]
12. The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance.
Ngo MT; Jeng HY; Kuo YC; Diony Nanda J; Brahmadhi A; Ling TY; Chang TS; Huang YH
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669204
[TBL] [Abstract][Full Text] [Related]
13. MiR-505 suppressed the growth of hepatocellular carcinoma cells via targeting IGF-1R.
Ren L; Yao Y; Wang Y; Wang S
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31160483
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma.
Desbois-Mouthon C; Baron A; Blivet-Van Eggelpoël MJ; Fartoux L; Venot C; Bladt F; Housset C; Rosmorduc O
Clin Cancer Res; 2009 Sep; 15(17):5445-56. PubMed ID: 19706799
[TBL] [Abstract][Full Text] [Related]
15. Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer.
Xian L; Zhao P; Chen X; Wei Z; Ji H; Zhao J; Liu W; Li Z; Liu D; Han X; Qian Y; Dong H; Zhou X; Fan J; Zhu X; Yin J; Tan X; Jiang D; Yu H; Cao G
Cell Oncol (Dordr); 2022 Oct; 45(5):1019-1036. PubMed ID: 36036881
[TBL] [Abstract][Full Text] [Related]
16. MiR-448 suppresses cell proliferation and glycolysis of hepatocellular carcinoma through inhibiting IGF-1R expression.
Wang Y; Chen X; Yao N; Gong J; Cao Y; Su X; Feng X; Tao M
J Gastrointest Oncol; 2022 Feb; 13(1):355-367. PubMed ID: 35284123
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of hepatocellular carcinoma cells with antrocinol, a novel, dual-specificity, small-molecule inhibitor of the KRAS and ERK oncogenic signaling pathways.
Hsu CH; Weng PW; Chen MY; Yeh CT; Setiawan SA; Yadav VK; Wu ATH; Tzeng DTW; Gong JX; Yang Z; Tzeng YM
Chem Biol Interact; 2023 Jan; 370():110329. PubMed ID: 36565974
[TBL] [Abstract][Full Text] [Related]
18. The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC.
Wang LH; Xu M; Fu LQ; Chen XY; Yang F
Sci Rep; 2018 Aug; 8(1):12776. PubMed ID: 30143678
[TBL] [Abstract][Full Text] [Related]
19. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma.
Shen YC; Ou DL; Hsu C; Lin KL; Chang CY; Lin CY; Liu SH; Cheng AL
Br J Cancer; 2013 Jan; 108(1):72-81. PubMed ID: 23257894
[TBL] [Abstract][Full Text] [Related]
20. MiR-503 inhibits hepatocellular carcinoma cell growth via inhibition of insulin-like growth factor 1 receptor.
Xiao Y; Tian Q; He J; Huang M; Yang C; Gong L
Onco Targets Ther; 2016; 9():3535-44. PubMed ID: 27366090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
